@Lopez I'm wondering, shorters and accumulators aside, whether it would be financially sane for a potential biopharma partner to consider trying to restrain the price if they knew they also were going to buy a share parcel as part of the agreement;
representing a 20% premium to a blended volume weighted average price calculated over three months, one month and one day.
It might mean some accumulation at opportune times over the past months to make the strategy cost positive. Just a thought.
Ann: Day 180 Survival Outcomes In aGvHD Phase 3 Trial, page-55
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.8¢ | 93.5¢ | $4.207M | 4.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 42268 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 48002 | 3 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |